Home / Research / Publications / Comparison of Trastuzumab Deruxtecan and Sacituzumab Govitecan in HER2-Negative Metastatic Breast Cancer A Large Real-World Data Analysis

Publications

Comparison of Trastuzumab Deruxtecan and Sacituzumab Govitecan in HER2-Negative Metastatic Breast Cancer A Large Real-World Data Analysis

Background

Trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) are antibody-drug conjugates (ADCs) increasingly used in HER2-negative breast cancer. We hypothesized that treatment benefit would vary across HER2-null, HER2-ultra-low, and HER2-low subgroups of HER2-negative breast cancer patients. We also aimed to study the clinical impact of different sequencing of the two ADCs. 

Download Publication
Learn More
Name(Required)